SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

A drug commonly used to treat type 2 diabetes may reduce excess fluid in the brains of patients with hydrocephalus, which could help treat the disease less invasively than current treatments, ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

The discovery that diabetes medication could potentially manage hydrocephalus occurred after Dr Magill observed significant ...